Latest & greatest articles for osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoarthritis

181. Surgical Management of Osteoarthritis of the Knee

Surgical Management of Osteoarthritis of the Knee 1 * See Appendix XIII for details regarding support SURGICAL MANAGEMENT OF OSTEOARTHRITIS OF THE KNEE EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors 12.4.15 Supported* by: Endorsed by: 2 Disclaimer This Clinical Practice Guideline was developed by an AAOS physician volunteer Guideline development group based on a systematic review of the current scientific and clinical (...) Surgeons 3 To View All AAOS Evidence-Based Guidelines and Appropriate Use Criteria in a User-Friendly Format, Please Visit the Orthoguidelines Web- Based App at www.orthoguidelines.org or by clicking the icon above! 4 SUMMARY OF RECOMMENDATIONS The following is a summary of the recommendations of the AAOS Clinical Practice Guideline on the Surgical Management of Osteoarthritis of the Knee. All readers of this summary are strongly urged to consult the full guideline and evidence report

American Academy of Orthopaedic Surgeons2015

182. Joint protection strategies for hand osteoarthritis

Joint protection strategies for hand osteoarthritis RACGP - Education about joint protection strategies: hand osteoarthritis Username Password Password security changes or call 1800 284 789 Search the RACGP website Your browser has 'Cookies' disabled, alert boxes will continue to appear without this feature. / / / / / Education about joint protection strategies: hand osteoarthritis HANDI Making non-drug interventions easier to find and use Education about joint protection strategies: hand (...) osteoarthritis Osteoarthritis is the leading cause of disability in older adults Intervention Education about joint protection strategies (i.e. techniques for doing everyday activities in ways that minimise strain on joints). Indication Pain from hand osteoarthritis (OA). The aim of the intervention is to lessen pain and improve functioning for people with hand OA. Symptomatic hand OA affects approximately 20% of people over 55 years of age. It has an impact on quality of life by causing variable levels

Handbook of Non-Drug interventions (HANDI)2015

183. Exercise effective for osteoarthritis of hip

Exercise effective for osteoarthritis of hip Exercise effective for osteoarthritis of hip | Cochrane Primary Care Top menu Trusted evidence. Informed decisions. Better health. Enter terms Exercise effective for osteoarthritis of hip Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2017 The Cochrane Collaboration | |

Cochrane PEARLS2014

184. Preoperative physical therapy for severe osteoarthritis of the hip

Preoperative physical therapy for severe osteoarthritis of the hip Preoperative physical therapy for severe osteoarthritis of the hip Preoperative physical therapy for severe osteoarthritis of the hip Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Preoperative physical therapy for severe osteoarthritis of the hip. Lansdale: HAYES, Inc.. Directory Publication (...) . 2014 Authors' objectives Physical therapy may be beneficial both before and after joint replacement surgery in patients with severe osteoarthritis (OA). In general, the goal of physical therapy in patients with OA is to increase function and physical activity despite pain and stiffness. Perioperative goals include faster recovery time, shorter hospital length of stay (LOS), and increased range of motion and function. Final publication URL The report may be purchased from: Indexing Status Subject

Health Technology Assessment (HTA) Database.2014

185. Intra-articular injection of cross-linked hyaluronans for treatment of shoulder osteoarthritis

Intra-articular injection of cross-linked hyaluronans for treatment of shoulder osteoarthritis Intra-articular injection of cross-linked hyaluronans for treatment of shoulder osteoarthritis Intra-articular injection of cross-linked hyaluronans for treatment of shoulder osteoarthritis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Intra-articular injection (...) of cross-linked hyaluronans for treatment of shoulder osteoarthritis. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Osteoarthritis (OA) is a degenerative disease of the joints that leads to pain and disability. OA of the shoulder is the result of deterioration of the articular surface of the humeral head and glenoid, specifically, degeneration of cartilage and narrowing of the glenohumeral joint space. There are medical and surgical treatment options

Health Technology Assessment (HTA) Database.2014

186. Intra-articular injection of non?cross-linked sodium hyaluronate for treatment of shoulder osteoarthritis

Intra-articular injection of non?cross-linked sodium hyaluronate for treatment of shoulder osteoarthritis Intra-articular injection of non–cross-linked sodium hyaluronate for treatment of shoulder osteoarthritis Intra-articular injection of non–cross-linked sodium hyaluronate for treatment of shoulder osteoarthritis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Intra-articular injection of non–cross-linked sodium hyaluronate for treatment of shoulder osteoarthritis. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Osteoarthritis (OA) is a degenerative disease of the joints that leads to pain and disability. OA of the shoulder is the result of deterioration of the articular surface of the humeral head and glenoid, specifically, degeneration of cartilage and narrowing of the glenohumeral joint space

Health Technology Assessment (HTA) Database.2014

187. Homeopathic remedies in the treatment of migraine and osteoarthritis: evidence note 53

Homeopathic remedies in the treatment of migraine and osteoarthritis: evidence note 53 Homeopathic remedies in the treatment of migraine and osteoarthritis: evidence note 53 Search the full site Search keywords Our on-going projects: Evidence note 53 Evidence note 53 Contact the SHTG team Contact Healthcare Improvement Scotland with any SHTG questions: Email: Lead Health Services Researcher Lead for SHTG SHTG Project Officer Evidence note 53 Are homeopathic remedies clinically and cost (...) effective in the treatment of migraine and osteoarthritis? Downloads Key points Published systematic reviews of homeopathy for migraine and osteoarthritis provide limited evidence on clinical effectiveness compared with standard care. Homeopathy for migraine has not been compared with active treatment in randomised controlled trials (RCTs), and only one of four RCTs found homeopathy to be superior to placebo. In three RCTs, drug treatments for osteoarthritis had similar or better effects on pain than

Evidence Notes from Healthcare Improvement Scotland2014

189. Osaflexan (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

Osaflexan (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/17 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 OSAFLEXAN 1178 mg, oral powder for solution in single-dose sachets Box of 30 single-dose sachets (CIP: 34009 397 018 2 0) Box of 90 single-dose sachets (CIP: 34009 575 860 6 5) Applicant: ROTTAPHARM S.A.R.L. INN Glucosamine (sulfate) ATC code (2012 (...) ) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 10 March 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) B/30 only Hospital use (French Public Health Code L.5123-2) B/30 and 90 Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." HAS - Medical, Economic and Public Health

Haute Autorite de sante2014

190. Structoflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Structoflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/13 TRANSPARENCY COMMITTEE Opinion 20 November 2013 STRUCTOFLEX 625 mg, hard capsule Box of 60 hard capsules (CIP: 34009 346 919 2) Applicant: PIERRE FABRE MEDICAMENT INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason for the review Re-assessment of the actual benefit (...) pursuant to the findings of the Transparency Committee in its opinion of 30 June 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123-2) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." The legally binding text is the original French version HAS - Medical, Economic and Public Health Assessment Division 2/13 Actual Benefit Insufficient Actual Benefit Therapeutic Use Due

Haute Autorite de sante2014

191. Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Voltaflex (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/8 The legally binding text is the original French version TRANSPARENCY C OMMITTEE Opinion 20 November 2013 VOLTAFLEX 625 mg, film-coated tablet B/60 tablets (CIP: 34009 384 573 2) Applicant: NOVARTIS SANTÉ FAMILIALE S.A.S. INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory drugs) Reason (...) for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 10 March 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee." HAS - Medical, Economic and Public Health Assessment Division 2/8 Actual Benefit Insufficient Actual Benefit Therapeutic Use Due to the very modest efficacy on pain and functional disability

Haute Autorite de sante2014

192. Flexea (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee

Flexea (Glucosamine (hydrochloride)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/17 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 FLEXEA 625 mg, tablet Box of 60 tablets (CIP: 34009 380 534 2 5) Box of 180 tablets (CIP: 34009 380 535 9 3) Applicant: EXPANSCIENCE INN Glucosamine (hydrochloride) ATC code (2012) M01AX05 (other non-steroidal anti-rheumatic anti-inflammatory (...) drugs) Reason for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 22 July 2009. List(s) concerned National Health Insurance (French Social Security Code L.162-17) only for the box of 60 Hospital use (French Public Health Code L.5123-2) for boxes of 60 and 180 Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee.” HAS - Medical, Economic and Public Health Assessment Division 2/17 AB

Haute Autorite de sante2014

193. Dolenio (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee

Dolenio (Glucosamine (sulfate)) - mild to moderate osteoarthritis of the knee HAS - Medical, Economic and Public Health Assessment Division 1/12 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 November 2013 DOLENIO 1178 mg, film-coated tablets Box of 30 tablets (CIP: 34009 393 133 1) DOLENIO 1178 mg, tablets in blister pack Box of 30 tablets (CIP: 34009 496 655 0) Applicant: BIOCODEX INN Glucosamine (sulfate) ATC code (2012) M01AX05 (other non-steroidal (...) anti-rheumatic anti-inflammatory drugs) Reason for the review Re-assessment of the actual benefit pursuant to the findings of the Transparency Committee in its opinion of 13 January 2010. List(s) concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123-2) Indication(s) concerned "Relief of symptoms in mild to moderate osteoarthritis of the knee. " HAS - Medical, Economic and Public Health Assessment Division 2/12 Actual Benefit

Haute Autorite de sante2014

194. Flector (diclofenac epolamine) - short-term symptomatic treatment of acute episodes of: extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; microcrystalline arthritis; osteoarthritis etc

Flector (diclofenac epolamine) - short-term symptomatic treatment of acute episodes of: extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; microcrystalline arthritis; osteoarthritis etc HAS - Medical, Economic and Public Health Assessment Division 1/39 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 FLECTOR 50 mg, granules for oral solution in single-dose sachets (...) Health Code L.5123-2) Indications concerned “In adults (aged over 15 years): short-term symptomatic treatment of acute episodes of: - extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; - microcrystalline arthritis; - osteoarthritis; - lumbar pain; - radicular pain.” HAS - Medical, Economic and Public Health Assessment Division 2/39 AB Extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis and bursitis The actual benefit of FLECTOR

Haute Autorite de sante2014

195. Altim (Cortivazol) - arthritis, osteoarthritis, tendinitis, bursitis, talalgia, carpal tunnel syndrome, Dupuytren's contracture, radiculalgia

Altim (Cortivazol) - arthritis, osteoarthritis, tendinitis, bursitis, talalgia, carpal tunnel syndrome, Dupuytren's contracture, radiculalgia HAS - Medical, Economic and Public Health Assessment Division 1/14 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 05 February 2014 ALTIM 3.75 mg/1.5 ml, suspension for injection 1 1.5 ml pre-filled syringe (CIP: 34009 313 579 8 8) APPLICANT: SANOFI-AVENTIS FRANCE INN (...) : - In intra-articular injection: inflammatory arthritis, advanced osteoarthritis. - In periarticular injection: tendinitis, bursitis. - In injection of soft tissue: talalgia, carpal tunnel syndrome, Dupuytren's contracture. - In epidural injection: radiculalgia" HAS - Medical, Economic and Public Health Assessment Division 2/14 Actual Benefit The Committee considers that the actual benefit of ALTIM remains substantial in rheumatological diseases: - In intra-articular injection: inflammatory arthritis

Haute Autorite de sante2014

196. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines

Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation CADTH. Viscosupplementation for the treatment of osteoarthritis of the knee: clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions Nine systematic reviews and eight evidence-based guidelines were identified regarding viscosupplementation for the treatment of patients with osteoarthritis of the knee. Final publication URL Indexing Status

Health Technology Assessment (HTA) Database.2014

197. 45-day mortality after 467 779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study.

45-day mortality after 467 779 knee replacements for osteoarthritis from the National Joint Registry for England and Wales: an observational study. BACKGROUND: Understanding the risk factors for early death after knee replacement could help to reduce the risk of mortality after this procedure. We assessed secular trends in death within 45 days of knee replacement for osteoarthritis in England and Wales, with the aim of investigating whether any change that we recorded could be explained (...) by alterations in modifiable perioperative factors. METHODS: We took data for knee replacements done for osteoarthritis in England and Wales between April 1, 2003, and Dec 31, 2011, from the National Joint Registry for England and Wales. Patient identifiers were used to link these data to the national mortality database and the Hospital Episode Statistics database to obtain details of death, sociodemographics, and comorbidity. We assessed mortality within 45 days by Kaplan-Meier analysis and assessed

Lancet2014

198. Prolotherapy: A nontraditional approach to knee osteoarthritis

Prolotherapy: A nontraditional approach to knee osteoarthritis Prolotherapy: A nontraditional approach to knee osteoarthritis Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Prolotherapy: A nontraditional approach to knee osteoarthritis View/ Open Date 2014-04 Format Metadata Abstract Recommend prolotherapy (...) for patients with knee osteoarthritis (OA) that does not respond to conventional therapies. URI Part of Citation Journal of Family Practice, 63(4) 2014: 206-208 Collections hosted by hosted by

PURLS2014

199. Osteoarthritis.

Osteoarthritis. In the clinic. Osteoarthritis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 24979462 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order (...) articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2014 Jul 1;161(1):ITC1-16. doi: 10.7326/0003-4819-161-1-201407010-01001. In the clinic. Osteoarthritis. . Erratum in Ann Intern Med. 2014 Jul 1;161(1):ITC1-17. Ann Intern Med. 2014 Aug 19;161(4):308. PMID: 24979462 DOI: [Indexed for MEDLINE] Publication type MeSH terms Substance Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text links

Annals of Internal Medicine2014

200. Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections

Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections Prescrire IN ENGLISH - Spotlight ''Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections '', 1 October 2013 {1} {1} {1} | | > > > Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  (...) Spotlight Osteoarthritis of the knee: avoid intra-articular hyaluronic acid injections At best, intra-articular hyaluronic acid injections give modest relief to patients suffering knee osteoarthritis pain, at the price of local reactions and sometimes severe adverse effects. In patients suffering knee osteoarthritis pain, above all treatment involves physical exercises and analgesics, chiefly paracetamol. Intra-articular hyaluronic acid injections are sometimes offered, but there is no proof

Prescrire2014